Fox Chase First in Region to Offer Newly FDA Approved Non-Invasive, Non-Ionizing Radiation Therapy to Treat Pain from Bone Metastases
PHILADELPHIA, PA (November 1, 2012)— Fox Chase Cancer Center is the first center in Pennsylvania to offer the newly U.S. Food and Drug Administration (FDA) approved ExAblate® MRI-guided focused ultrasound as a therapy to treat pain from bone metastases in patients who do not respond or cannot undergo radiation treatment for their pain. This is the second FDA approval for ExAblate, which has been used widely since it was approved in 2004 as a non-invasive, outpatient, therapy for uterine fibroids.